Effect of Simethicone on Reducing Bowel Interference During Tubal Resection
Primary Purpose
Sterility, Postpartum
Status
Completed
Phase
Phase 3
Locations
Thailand
Study Type
Interventional
Intervention
Simethicone 80 MG
Sponsored by
About this trial
This is an interventional treatment trial for Sterility, Postpartum
Eligibility Criteria
Inclusion Criteria:
- Women requesting postpartum sterilization by minilaparotomic tubal resection after vaginal delivery at Faculty of Medicine, Chiang Mai University
Exclusion Criteria:
- Pre-pregnancy BMI > 25 kg/m2
- Intraoperative general anesthesia or epidural anesthesia
- Previous abdominal surgery except for appendectomy
- Known bowel disorder including Crohn's disease, ulcerative colitis, previous bowel surgery
Sites / Locations
- Department of OB-GYN, Faculty of Medicine, Chiang Mai University
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Simethicone
No simethicone
Arm Description
Each woman in the intervention group will be given Simethicone (Air-X®; 80 mg) 2 tablets chewing with water 50 ml at 2-8 hours before surgery.
The women will not be given Simethicone.
Outcomes
Primary Outcome Measures
Operative difficulty score
Operative difficulty scores will be assessed at the end of the operation by the operating surgeon. The surgeon will rate the difficulty of the operation from 0 to 10 according to the 10-cm visual analog scale with "0" represents the easiest operation and "10" represents the hardest operation.
Secondary Outcome Measures
Operation time (Total)
The time duration from skin incision to completion of skin closure
Operation time (Intraabdominal)
The time duration from first entering abdominal cavity to start closing the abdominal peritoneum.
Full Information
NCT ID
NCT03429621
First Posted
January 31, 2018
Last Updated
February 4, 2020
Sponsor
Chiang Mai University
1. Study Identification
Unique Protocol Identification Number
NCT03429621
Brief Title
Effect of Simethicone on Reducing Bowel Interference During Tubal Resection
Official Title
Effect of Simethicone on Reducing Bowel Interference During Minilaparotomy for Tubal Resection : a Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
February 2020
Overall Recruitment Status
Completed
Study Start Date
March 8, 2018 (Actual)
Primary Completion Date
February 28, 2019 (Actual)
Study Completion Date
March 31, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Chiang Mai University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Tubal ligation is an everyday procedure for permanent female sterilization. It is usually performed after a vaginal delivery. Minilaparotomy is generally performed by doing small incision at infraumbilical area. This minimal access surgery requires adequate operative field exposure. Bowel interference, which obscures visualization of the operative field has been recognized as one of the major obstacles during this procedure. We found problems while doing surgery in small space and one of them is bowel interferance which obscures vision. This could lead to prolonged operation and complications. Simethicone is an antifoaming agent that use in bowel preparation prior to various procedures including laparoscopy, colonoscopy, endoscopy, and open major abdominal operations. Simethicone is proven to break the bubble and reduce intraluminal gas. This effect could result in reduction of bowel dilatation that interfere with the proper identification of the adnexal area. Benefit of taking simethicone prior to do minilaparotomy for tubal resection has not been examined.
Objectives: To examine the effect of simethicone on reducing bowel interference during minilaparotomy for tubal resection.
Design: A randomized controlled trial in women, age 20-45 years, undergoing postpartum sterilization after vaginal delivery at Faculty of Medicine, Chiang Mai University hospital. The participants will be randomly assigned into one of two study groups: intervention (taking simethicone) and control (not taking simethicone). For the intervention group, each woman will take simethicone (80 mg) 2 tablet chewing with water 50 ml at 2-8 hours before surgery. Fasting at least 6 hours before surgery. For the control group, the women will receive the same standard perioperative care without taking simethicone. The primary outcome measure will be surgeon-rated operative difficulty score, which is a visual analog scale based on assess from exposure of to the operative field in visual analog scale by surgeon. The secondary outcome will be operative time and incidence of intraoperative and postoperative complications.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sterility, Postpartum
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Care ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
120 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Simethicone
Arm Type
Experimental
Arm Description
Each woman in the intervention group will be given Simethicone (Air-X®; 80 mg) 2 tablets chewing with water 50 ml at 2-8 hours before surgery.
Arm Title
No simethicone
Arm Type
No Intervention
Arm Description
The women will not be given Simethicone.
Intervention Type
Drug
Intervention Name(s)
Simethicone 80 MG
Intervention Description
Simethicone (Air-X®; 80 mg) 2 tablets chewing with water 50 ml at 2-8 hours before surgery
Primary Outcome Measure Information:
Title
Operative difficulty score
Description
Operative difficulty scores will be assessed at the end of the operation by the operating surgeon. The surgeon will rate the difficulty of the operation from 0 to 10 according to the 10-cm visual analog scale with "0" represents the easiest operation and "10" represents the hardest operation.
Time Frame
At the end of operation (within 1 hour after the completion of the operation)
Secondary Outcome Measure Information:
Title
Operation time (Total)
Description
The time duration from skin incision to completion of skin closure
Time Frame
From the start of skin incision creation to the completion of skin closure (up to 2 hours)
Title
Operation time (Intraabdominal)
Description
The time duration from first entering abdominal cavity to start closing the abdominal peritoneum.
Time Frame
From first entering abdominal cavity to start closing the abdominal peritoneum (up to 2 hours)
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Women requesting postpartum sterilization by minilaparotomic tubal resection after vaginal delivery at Faculty of Medicine, Chiang Mai University
Exclusion Criteria:
Pre-pregnancy BMI > 25 kg/m2
Intraoperative general anesthesia or epidural anesthesia
Previous abdominal surgery except for appendectomy
Known bowel disorder including Crohn's disease, ulcerative colitis, previous bowel surgery
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kittipat Charoenkwan, MD, MSc
Organizational Affiliation
Faculty of Medicine, Chiang Mai University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of OB-GYN, Faculty of Medicine, Chiang Mai University
City
Chiang Mai
ZIP/Postal Code
50200
Country
Thailand
12. IPD Sharing Statement
Learn more about this trial
Effect of Simethicone on Reducing Bowel Interference During Tubal Resection
We'll reach out to this number within 24 hrs